Physician profile
Timothy M Lynch
NPI 1659313898
$265,351.38
in general payments reported to CMS, 2019-2025
11 companies · $45K in 2025
The $45K reported for 2025 was more than what 96% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $19K · 2021: $38K · 2022: $37K · 2023: $50K · 2024: $56K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $75K · Honoraria: $49K · Travel and Lodging: $16K · Food and Beverage: $6,670 · Consulting Fee: $3,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $74,889.50 |
| Honoraria | $49,225.00 |
| Travel and Lodging | $16,461.46 |
| Food and Beverage | $6,670.34 |
| Consulting Fee | $3,618.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $99,871.43 | 2020-2025 | Xcopri |
| Neurelis, INC. | $79,598.51 | 2020-2025 | Valtoco |
| Livanova USA, INC. | $46,163.88 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Jazz Pharmaceuticals INC. | $32,051.45 | 2022-2025 | |
| Greenwich Biosciences, INC. | $7,063.68 | 2019-2021 | |
| Ucb, INC. | $331.86 | 2023-2025 | Fintepla, Nayzilam, Briviact |
| Catalyst Pharmaceuticals, INC. | $102.85 | 2023-2025 | Fycompa |
| Neurocrine Biosciences, INC. | $54.77 | 2025 | |
| Abbvie INC. | $52.89 | 2021-2025 | |
| Vertex Pharmaceuticals Incorporated | $40.12 | 2025 | |
| Tg Therapeutics, INC. | $19.94 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.